

Joaquim Bosch-Barrera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2822856/publications.pdf>

Version: 2024-02-01

78
papers

2,838
citations

186265

28
h-index

189892

50
g-index

82
all docs

82
docs citations

82
times ranked

5139
citing authors

#	ARTICLE	IF	CITATIONS
1	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. <i>European Journal of Cancer</i> , 2022, 167, 142-148.	2.8	32
2	Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. <i>Pharmaceuticals</i> , 2022, 15, 19.	3.8	2
3	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765.	30.7	30
4	The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. <i>Autophagy</i> , 2021, 17, 1349-1366.	9.1	72
5	SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 980-987.	2.4	16
6	Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2141.	3.7	11
7	Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor- α positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. <i>European Journal of Cancer</i> , 2021, 149, 61-72.	2.8	21
8	Lung Cancer Management with Silibinin: A Historical and Translational Perspective. <i>Pharmaceuticals</i> , 2021, 14, 559.	3.8	14
9	Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. <i>BMC Cancer</i> , 2021, 21, 977.	2.6	5
10	Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. <i>Cancers</i> , 2021, 13, 4168.	3.7	8
11	Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma. <i>Cancers</i> , 2021, 13, 5320.	3.7	4
12	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 1770.	2.4	42
13	Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. <i>Cancer Treatment Reviews</i> , 2020, 89, 102067.	7.7	48
14	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 1757.	3.7	17
15	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. <i>Aging</i> , 2020, 12, 8-34.	3.1	99
16	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. <i>Aging</i> , 2020, 12, 4794-4814.	3.1	38
17	Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity. <i>Aging</i> , 2020, 12, 21057-21075.	3.1	2
18	The Medical Oncology resident mentor: situation and workload. <i>Clinical and Translational Oncology</i> , 2019, 21, 304-313.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A. <i>Nutrients</i> , 2019, 11, 1656.	4.1	26
20	Revisiting silibinin as a novobiocin-like Hsp90 α -C-terminal inhibitor: Computational modeling and experimental validation. <i>Food and Chemical Toxicology</i> , 2019, 132, 110645.	3.6	16
21	Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets. <i>Food and Chemical Toxicology</i> , 2019, 131, 110529.	3.6	15
22	Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns. <i>Clinical Lung Cancer</i> , 2019, 20, e421-e429.	2.6	27
23	The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. <i>Food and Chemical Toxicology</i> , 2019, 128, 35-45.	3.6	27
24	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1606.	4.1	32
25	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. <i>Carcinogenesis</i> , 2019, 40, 27-40.	2.8	14
26	Silibinin is a direct inhibitor of STAT3. <i>Food and Chemical Toxicology</i> , 2018, 116, 161-172.	3.6	52
27	Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer. <i>Anti-Cancer Drugs</i> , 2018, 29, 380-383.	1.4	4
28	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. <i>Frontiers in Endocrinology</i> , 2018, 9, 657.	3.5	85
29	65P Fatty acid synthase (FASN) inhibition effect on EGFR TKIs sensitive and resistant cells. <i>Journal of Thoracic Oncology</i> , 2018, 13, S34-S35.	1.1	0
30	STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. <i>Nature Medicine</i> , 2018, 24, 1024-1035.	30.7	285
31	Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. <i>Oncotarget</i> , 2018, 9, 27074-27086.	1.8	8
32	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017, 108, 154-160.	2.0	18
33	Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. <i>Cell Cycle</i> , 2017, 16, 1022-1028.	2.6	19
34	A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 212-216.	2.0	35
35	Targeting STAT3 with silibinin to improve cancer therapeutics. <i>Cancer Treatment Reviews</i> , 2017, 58, 61-69.	7.7	86
36	EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. <i>Oncology Reports</i> , 2017, 38, 263-270.	2.6	11

#	ARTICLE	IF	CITATIONS
37	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. <i>Oncotarget</i> , 2017, 8, 99223-99236.	1.8	9
38	<i>BRCA1</i> haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. <i>Oncotarget</i> , 2017, 8, 35019-35032.	1.8	12
39	The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?. <i>Translational Cancer Research</i> , 2017, 6, S201-S204.	1.0	2
40	Ethics competences in the undergraduate medical education curriculum: the Spanish experience. <i>Croatian Medical Journal</i> , 2016, 57, 493-503.	0.7	11
41	Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. <i>Oncotarget</i> , 2016, 7, 32006-32014.	1.8	47
42	Somatic <i>DICER1</i> mutations in adult-onset pulmonary blastoma. <i>European Respiratory Journal</i> , 2016, 47, 1879-1882.	6.7	22
43	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in <i>ALK</i> -rearranged lung cancer. <i>Cell Cycle</i> , 2016, 15, 3413-3418.	2.6	49
44	Activation of the methylation cycle in cells reprogrammed into a stem cell-like state. <i>Oncoscience</i> , 2016, 2, 958-967.	2.2	30
45	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in <i>NRAS</i> -mutant metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 82185-82199.	1.8	16
46	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , 2015, 5, 17499.	3.3	55
47	Paraneoplastic Limbic Encephalitis in a Male with Squamous Cell Carcinoma of the Lung. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
55	Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. <i>Oncotarget</i> , 2014, 5, 8306-8316.	1.8	94
56	Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient. <i>Anticancer Research</i> , 2014, 34, 4323-7.	1.1	21
57	Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. <i>Journal of Translational Medicine</i> , 2013, 11, 13.	4.4	38
58	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. <i>Food and Chemical Toxicology</i> , 2013, 60, 360-368.	3.6	53
59	Zoledronic acid in lung cancer with bone metastases: a review. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 421-426.	2.4	13
60	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. <i>Scientific Reports</i> , 2013, 3, 2560.	3.3	74
61	Stem cell-like ALDH ^{bright} cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. <i>Cell Cycle</i> , 2013, 12, 3390-3404.	2.6	65
62	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. <i>Scientific Reports</i> , 2013, 3, 2459.	3.3	67
63	Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. <i>British Journal of Cancer</i> , 2012, 106, 1406-1414.	6.4	42
64	Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205. <i>Cell Cycle</i> , 2012, 11, 1235-1246.	2.6	56
65	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. <i>Oncology Reports</i> , 2012, 27, 1887-92.	2.6	5
66	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. <i>Cell Cycle</i> , 2012, 11, 865-870.	2.6	37
67	The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. <i>Clinical and Translational Oncology</i> , 2012, 14, 835-841.	2.4	6
68	Metformin-induced preferential killing of breast cancer initiating CD44 ⁺ CD24 ^{low} cells is sufficient to overcome primary resistance to trastuzumab in HER2 ⁺ human breast cancer xenografts. <i>Oncotarget</i> , 2012, 3, 395-398.	1.8	134
69	Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. <i>Lung Cancer</i> , 2011, 71, 244.	2.0	1
70	Metformin: Multi-faceted protection against cancer. <i>Oncotarget</i> , 2011, 2, 896-917.	1.8	263
71	Costs and Ethical Issues Related to First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective. <i>Clinical Lung Cancer</i> , 2011, 12, 335-340.	2.6	2
72	Direct antitumour activity of zoledronic acid: preclinical and clinical data. <i>Clinical and Translational Oncology</i> , 2011, 13, 148-155.	2.4	16

#	ARTICLE	IF	CITATIONS
73	Bisphosphonates in Breast Cancer: From Metastasis to Prevention. <i>Current Breast Cancer Reports</i> , 2010, 2, 222-230.	1.0	1
74	Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report. <i>International Archive of Medicine</i> , 2010, 3, 6.	1.2	6
75	Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone. <i>Clinical and Translational Oncology</i> , 2009, 11, 765-766.	2.4	3
76	Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 64, 124-126.	2.0	9
77	Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer. <i>Onkologie</i> , 2009, 32, 580-584.	0.8	24
78	Primary bone lymphoma of the mandible and thyroid incidentaloma identified by 18FDG PET/CT: a case report. <i>Cases Journal</i> , 2009, 2, 6384.	0.4	9